Prestige Consumer Healthcare (PBH) Liabilities and Shareholders Equity (2011 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Liabilities and Shareholders Equity of $3.5 billion for Q4 2025, up 4.96% year-over-year from $3.3 billion in Q4 2024, and up 1.52% quarter-over-quarter from $3.4 billion in Q3 2025.
Prestige Consumer Healthcare (PBH) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $3.5 billion for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 4.96% year-over-year to $3.5 billion; the TTM figure through Dec 2025 stood at $13.8 billion (up 3.76% YoY), while the FY2025 annual figure was $3.4 billion, up 2.53% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $3.5 billion, up from $3.4 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.7 billion in Q4 2022, with the low at $3.3 billion in Q2 2024.
- The 5-year median for Liabilities and Shareholders Equity is $3.4 billion (2021), against an average of $3.5 billion.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity increased 7.04% in 2022, then dropped 10.93% in 2023.
- Prestige Consumer Healthcare's Liabilities and Shareholders Equity stood at $3.7 billion in 2021, then grew by 2.47% to $3.7 billion in 2022, then slipped by 10.93% to $3.3 billion in 2023, then retreated by 0.31% to $3.3 billion in 2024, then rose by 4.96% to $3.5 billion in 2025.
- Business Quant data shows PBH's Liabilities and Shareholders Equity at $3.5 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.4 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 6.18 Bn |
| 10 | Prestige Consumer Healthcare | 2.42 Bn | 2.36 Bn | - | 3.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.49 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Sep 30, 2025 | 3.44 Bn |
| Jun 30, 2025 | 3.43 Bn |
| Mar 31, 2025 | 3.40 Bn |
| Dec 31, 2024 | 3.33 Bn |
| Sep 30, 2024 | 3.32 Bn |
| Jun 30, 2024 | 3.31 Bn |
| Mar 31, 2024 | 3.32 Bn |
| Dec 31, 2023 | 3.34 Bn |
| Sep 30, 2023 | 3.33 Bn |
| Jun 30, 2023 | 3.35 Bn |
| Mar 31, 2023 | 3.35 Bn |
| Dec 31, 2022 | 3.75 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 3.68 Bn |
| Mar 31, 2022 | 3.67 Bn |
| Dec 31, 2021 | 3.66 Bn |
| Sep 30, 2021 | 3.68 Bn |
| Jun 30, 2021 | 3.56 Bn |